Matches in DBpedia 2015-10 for { <http://dbpedia.org/resource/CERC-301> ?p ?o }
Showing triples 1 to 55 of
55
with 100 triples per page.
- CERC-301 abstract "CERC-301 (formerly known as MK-0657) is an orally-active, selective NMDA receptor subunit 2B (NR2B) antagonist which is under development by Cerecor in the United States as an adjunctive therapy for treatment-resistant depression (TRD). In November 2013, phase II clinical trials were initiated, and in the same month, CERC-301 received Fast Track Designation from the Food and Drug Administration for TRD.A pilot study was published in 2012, and a phase 2 trial was completed in 2014.".
- CERC-301 iupacName "4-Methylbenzyl (3S,4R)-3-fluoro-4-[(2-pyrimidinylamino)methyl]-1-piperidinecarboxylate".
- CERC-301 thumbnail CERC-301.svg?width=300.
- CERC-301 wikiPageExternalLink cerc-301.php.
- CERC-301 wikiPageID "43273539".
- CERC-301 wikiPageLength "3407".
- CERC-301 wikiPageOutDegree "18".
- CERC-301 wikiPageRevisionID "670409035".
- CERC-301 wikiPageWikiLink 4-Chlorokynurenine.
- CERC-301 wikiPageWikiLink ALKS-5461.
- CERC-301 wikiPageWikiLink AV-101.
- CERC-301 wikiPageWikiLink Category:Antidepressants.
- CERC-301 wikiPageWikiLink Category:NMDA_receptor_antagonists.
- CERC-301 wikiPageWikiLink Cerecor.
- CERC-301 wikiPageWikiLink Clinical_trial.
- CERC-301 wikiPageWikiLink Esketamine.
- CERC-301 wikiPageWikiLink FDA_Fast_Track_Development_Program.
- CERC-301 wikiPageWikiLink Fast_Track_Designation.
- CERC-301 wikiPageWikiLink Food_and_Drug_Administration.
- CERC-301 wikiPageWikiLink GRIN2B.
- CERC-301 wikiPageWikiLink NMDA_receptor.
- CERC-301 wikiPageWikiLink NRX-1074.
- CERC-301 wikiPageWikiLink NSI-189.
- CERC-301 wikiPageWikiLink Phases_of_clinical_research.
- CERC-301 wikiPageWikiLink Rapastinel.
- CERC-301 wikiPageWikiLink Receptor_antagonist.
- CERC-301 wikiPageWikiLink Treatment-resistant_depression.
- CERC-301 wikiPageWikiLink United_States.
- CERC-301 wikiPageWikiLinkText "CERC-301".
- CERC-301 hasPhotoCollection CERC-301.
- CERC-301 imagefile "CERC-301.svg".
- CERC-301 imagesize "200".
- CERC-301 iupacname "4".
- CERC-301 wikiPageUsesTemplate Template:Antidepressants.
- CERC-301 wikiPageUsesTemplate Template:Chembox.
- CERC-301 wikiPageUsesTemplate Template:Glutamatergics.
- CERC-301 wikiPageUsesTemplate Template:Nervous-system-drug-stub.
- CERC-301 wikiPageUsesTemplate Template:Reflist.
- CERC-301 subject Category:Antidepressants.
- CERC-301 subject Category:NMDA_receptor_antagonists.
- CERC-301 hypernym Antagonist.
- CERC-301 type ChemicalCompound.
- CERC-301 type ChemicalSubstance.
- CERC-301 type Drug.
- CERC-301 type ChemicalObject.
- CERC-301 type Thing.
- CERC-301 type Q11173.
- CERC-301 comment "CERC-301 (formerly known as MK-0657) is an orally-active, selective NMDA receptor subunit 2B (NR2B) antagonist which is under development by Cerecor in the United States as an adjunctive therapy for treatment-resistant depression (TRD). In November 2013, phase II clinical trials were initiated, and in the same month, CERC-301 received Fast Track Designation from the Food and Drug Administration for TRD.A pilot study was published in 2012, and a phase 2 trial was completed in 2014.".
- CERC-301 label "CERC-301".
- CERC-301 sameAs m.0114khkh.
- CERC-301 sameAs Q18205913.
- CERC-301 sameAs Q18205913.
- CERC-301 wasDerivedFrom CERC-301?oldid=670409035.
- CERC-301 depiction CERC-301.svg.
- CERC-301 isPrimaryTopicOf CERC-301.